. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: Int J Parasitol. 2011 Jan 11;41(5):545–552. doi: 10.1016/j.ijpara.2010.12.006

Table 2.

Summary of type and extent of inhibition for selected compounds against Leishmania mexicana arginase (LmARG) and human ARGI (HsARGI). The extent and type of inhibition for LmARG and HsARGI were determined by Dixon plot analysis or (for those marked with ^'a') by calculation from panel data assuming the type of inhibition shown in the final column and using equations (1) and (2) (Section 2.8).

Inhibitor	K_i vs. LmARG	K_i vs. HsARGI	Type of Inhibition
ABH	1.3 µM	3.5 µM	Competitive
BEC	~10 µM	14 µM^a	Competitive
nor-NOHA	~50 µM^*	~10 µM^a	Competitive
NOHA	85 µM	~70 µM^a	Competitive
8-Aminoguanine	< 2 mM	N/A	Uncompetitive
L-Cysteine	11 mM	> 30 mM^a	Competitive
Trypanothione	< 5 mM	< 5 mM^a	Uncompetitive

ABH, 2(S)-amino-6-boronohaxanoic acid; BEC, S-(2-boronoethyl)-L-cysteine; nor-NOHA, N^ω-Hydroxy-nor-L-arginine; NOHA, N^ω-Hydroxy-L-arginine.